NEW
YORK, July 16, 2024 /PRNewswire/ -- The global
uterine fibroid (UF) treatment device market size is estimated
to grow by USD 3.03 billion from
2024-2028, according to Technavio. The market is estimated to grow
at a CAGR of 9.45% during the forecast period. Increase
in healthcare expenditure is driving market growth, with
a trend towards improving healthcare systems in emerging
economies. However, high cost of treatment of uterine fibroid
poses a challenge. Key market players include Boston
Scientific Corp., Conmed Corp., Gynesonics Inc., Hologic Inc.,
INSIGHTEC Ltd., KARL STORZ SE and
Co. KG, Lumenis Be Ltd., Medtronic Plc, Merit Medical Systems Inc.,
Minerva Surgical Inc., Olympus Corp., and The Cooper Companies
Inc..
Get a detailed analysis on regions, market
segments, customer landscape, and companies- View the
snapshot of this report
Uterine Fibroid (UF)
Treatment Device Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2017 - 2021
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
9.45%
|
Market growth
2024-2028
|
USD 3034.4
million
|
Market
structure
|
Concentrated
|
YoY growth 2022-2023
(%)
|
8.42
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
33%
|
Key
countries
|
US, Japan, Germany,
China, and Canada
|
Key companies
profiled
|
Boston Scientific
Corp., Conmed Corp., Gynesonics Inc., Hologic Inc., INSIGHTEC Ltd.,
KARL STORZ SE and Co. KG, Lumenis Be Ltd., Medtronic Plc, Merit
Medical Systems Inc., Minerva Surgical Inc., Olympus Corp., and The
Cooper Companies Inc.
|
Market Driver
In the rapidly evolving healthcare landscape of emerging
economies, the demand for medical devices, including uterine
fibroid treatment devices, is increasing. Factors such as
population growth, expanding middle class, and improving healthcare
infrastructure are driving this trend. The BRICS countries,
including Brazil, Russia, India, China,
and South Africa, represent
significant opportunities for medical device manufacturers. These
economies, which account for over 50% of the global GDP, are
experiencing a rise in gynecological diseases, including uterine
fibroids. Sedentary lifestyles and obesity are contributing factors
to the increasing prevalence of uterine fibroids. The expanding
middle class in these countries is gaining access to private
medical insurance, leading to an increased demand for
cost-effective healthcare solutions. While local companies are
making efforts to innovate and offer affordable products, there is
still significant potential for established global players in these
markets. The attention of global institutional investors towards
healthcare infrastructure in these economies is further fueling the
growth potential for medical devices, including uterine fibroid
treatment devices, during the forecast period.
The Uterine Fibroid (UF) Treatment Device Market is witnessing
significant growth due to the increasing prevalence of uterine
myomas, or benign tumors, also known as leiomyomas. These
non-cancerous growths can cause symptoms such as anemia, excessive
menstrual bleeding, pelvic pain, bloating, increased urinary
frequency, and reproductive dysfunction. Leuprolide, Goserelin, and
Triptorelin are hormonal treatments used to shrink fibroids.
Devices using Progesterone, Levonorgestrel, and Mefenamic acid are
also popular. Risk factors for UF include race, age, familial
predisposition, premenopausal state, hypertension, and overweight.
New trends in UF treatment include outpatient centers, home
healthcare services, telemedicine platforms, and minimally invasive
procedures like myomectomy and myolysis. Other treatments include
Raloxifene. Symptoms like frequent urination and infertility can
significantly impact quality of life, making effective treatment
essential.
Discover 360° analysis of this market. For
complete information, schedule your consultation - Book
Here!
Market Challenges
- The global uterine fibroid treatment device market faces a
significant challenge due to the high cost of these devices and
associated procedures. This financial barrier can limit demand, as
many patients find the cost prohibitive, particularly those without
insurance coverage. For instance, the cost of hysterectomy ranges
from USD9,661 to USD22,534, while laparoscopic myomectomy
costs between USD8,062 and
USD11,432 in the US. The cost of
purchasing, maintaining, and upgrading these devices can also be a
burden for healthcare providers, leading to delays in adoption. In
developing economies, the lack of insurance coverage for uterine
fibroid treatments can prevent many patients from accessing these
procedures, leading to non-adherence and hindering market growth.
Therefore, the high cost of uterine fibroid treatments remains a
significant obstacle to market expansion during the forecast
period.
- Uterine fibroids (UF), a common benign tumor in women, can
cause excessive menstrual bleeding, pelvic pain, infertility, and
frequent urination. Risk factors include race, age, familial
predisposition, premenopausal state, hypertension, and overweight.
Traditional hysterectomy, an invasive treatment, involves larger
incisions and long recovery time. However, minimally invasive
procedures using laparoscopic, ablation, and embolization
techniques offer smooth muscle cell reduction with smaller
incisions, speedy recovery, and fewer side effects. Technologically
sophisticated technologies like radiofrequency ablation (RFA) are
non-surgical alternatives. The Uterine Fibroid (UF) Treatment
Device Market faces challenges in promoting minimally invasive
procedures due to fibroids' high prevalence and severe
complications. Organizations like the White Dress Project, Healthy
Women, and the Fibroids Project aim to raise fibroids awareness
during Fibroids Awareness Month. Contemporary OB/GYN emphasizes the
importance of minimally invasive techniques, including laparoscopic
and ablation techniques, to address the growing demand for less
invasive procedures.
For more insights on driver and
challenges - Request a sample report!
Segment Overview
This uterine fibroid (uf) treatment device market report
extensively covers market segmentation by
- Therapeutic Area
- 1.1 Invasive treatment
- 1.2 Minimally invasive treatment
- 1.3 Non-invasive treatment
- Technology
- 2.1 Surgical techniques
- 2.2 Laparoscopic techniques
- 2.3 Ablation techniques
- 2.4 Embolization techniques
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Invasive treatment- The invasive treatment
segment of the global uterine fibroid (UF) treatment device market
is currently dominating due to the popularity of surgical methods
such as hysterectomy and myomectomy. These procedures offer a high
degree of assurance for physicians regarding efficacy, safety, and
long-term outcomes. For instance, Hologic's Thermachoice III
Uterine Balloon Therapy System is a hysterectomy aid that reshapes
the uterus to remove fibroids and reduce bleeding. The increasing
incidences of uterine fibroids, the accuracy of surgical
procedures, and the permanent solution they provide are driving the
demand for invasive treatments. However, factors like patient age,
reproductive status, and fibroid size, number, and location
influence the preference for invasive methods. Minimally invasive
and noninvasive treatments like MRgFUS are gaining traction due to
their advantages, including shorter recovery time, lower risk of
complications, and minimal scarring. This trend may impact the
growth of the invasive treatment segment during the forecast
period.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data
(2017-2021) - Download a Sample Report
Learn and explore more about Technavio's in-depth research
reports
The global urethral dilator market is experiencing steady growth
driven by rising cases of urinary tract conditions. Technological
advancements in minimally invasive procedures and increasing
healthcare expenditure are key factors fueling market
expansion.
The global endometriosis market is witnessing significant growth
due to heightened awareness, improved diagnostics, and expanding
treatment options. Rising prevalence among women of reproductive
age and advancements in therapies are pivotal in shaping market
dynamics.
The global IVF devices market is growing robustly, propelled by
increasing infertility rates worldwide and advancements in assisted
reproductive technologies. Demand for sophisticated equipment and
supportive regulatory frameworks are key factors bolstering market
growth.
Research Analysis
Uterine fibroids (UF), also known as leiomyomas, are benign
tumors made up of smooth muscle cells that develop in the uterus.
They are a common condition among middle-aged women, particularly
those of African descent, with a high prevalence in premenopausal
women. Risk factors include familial predisposition, race, age,
premenopausal state, hypertension, and overweight. Symptoms include
excessive menstrual bleeding, pelvic pain, and frequent urination.
Traditional treatments include hysterectomy, but less invasive
procedures are gaining popularity. Technologically sophisticated
technologies, such as minimally invasive procedures using
morcellators, offer a non-surgical alternative. Contemporary OB/GYN
reports that severe complications can arise from the use of
morcellators, leading to the development of collagen-degrading
enzymes. Minimally invasive procedures are the future of UF
treatment, providing effective relief with fewer risks and quicker
recovery times.
Market Research Overview
Uterine fibroids (UF), also known as leiomyomas or myomas, are
benign tumors made up of smooth muscle cells that develop in the
uterus. These non-cancerous growths can cause various symptoms such
as excessive menstrual bleeding, pelvic pain, infertility, and
frequent urination. Risk factors for developing UF include race,
age, familial predisposition, premenopausal state, hypertension,
and overweight. Traditional treatments for UF include hysterectomy,
which involves larger incisions and longer recovery times, and
invasive surgical procedures. However, minimally invasive
treatments, such as laparoscopic and hysteroscopic procedures, have
gained popularity due to their smaller incisions, speedy recovery,
and fewer side effects. These contemporary techniques include
ablation techniques like radiofrequency ablation (RFA),
embolization techniques, and non-surgical alternatives like uterine
fibroid embolization (UFE). The UF treatment device market is
witnessing significant growth due to the high prevalence of
fibroids in middle-aged women and the availability of
technologically sophisticated technologies. The market includes
various players offering minimally invasive procedures through
outpatient centers, home healthcare services, and telemedicine
platforms. Symptoms of UF can include anemia, bloating, increased
urinary frequency, and reproductive dysfunction. Common medications
used to manage symptoms include Progesterone, Levonorgestrel,
Mefenamic acid, Raloxifene, Leuprolide, Goserelin, and Triptorelin.
Morcellators are also used in minimally invasive myomectomy
procedures to minimize the size of the fibroids before removal.
Fibroids Awareness Month, The White Dress Project, Healthy Women,
and The Fibroids Project are some organizations dedicated to
raising awareness and providing resources for those affected by
UF.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Therapeutic Area
-
- Invasive Treatment
- Minimally Invasive Treatment
- Non-invasive Treatment
- Technology
-
- Surgical Techniques
- Laparoscopic Techniques
- Ablation Techniques
- Embolization Techniques
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/uterine-fibroid-uf-treatment-device-market-size-is-set-to-grow-by-usd-3-03-billion-from-2024-2028--increase-in-healthcare-expenditure-boost-the-market-technavio-302197001.html
SOURCE Technavio